These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 26152804

  • 1. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, Ardizzoni A.
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F, Lambros L, Le Flahec G, Marcorelles P, Uguen A.
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [Abstract] [Full Text] [Related]

  • 3. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.
    Nambirajan A, Sood R, Khatoon W, Malik PS, Mohan A, Jain D.
    Arch Pathol Lab Med; 2024 Aug 01; 148(8):928-937. PubMed ID: 38054562
    [Abstract] [Full Text] [Related]

  • 4. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F, Rossi G, Cozzolino I, Montella M, Micheli M, Bogina G, Munari E, Brunelli M, Franco R.
    J Clin Pathol; 2020 Feb 01; 73(2):96-101. PubMed ID: 31562206
    [Abstract] [Full Text] [Related]

  • 5. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F, Miccoli M, Fontanini G.
    Cancer Cytopathol; 2014 Jun 01; 122(6):445-53. PubMed ID: 24648382
    [Abstract] [Full Text] [Related]

  • 6. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T, Savic S, Barascud A, Baschiera B, Bihl M, Grilli B, Herzog M, Rebetez J, Bubendorf L.
    Cancer Cytopathol; 2018 Jun 01; 126(6):421-429. PubMed ID: 29451745
    [Abstract] [Full Text] [Related]

  • 7. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM, Russell PA, Wright G, Wainer Z, Pang JM, Henricksen LA, Singh S, Stanislaw S, Grille J, Roberts E, Solomon B, Fox SB.
    J Thorac Oncol; 2015 Apr 01; 10(4):611-8. PubMed ID: 25789833
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC.
    Lung Cancer; 2017 Sep 01; 111():79-83. PubMed ID: 28838404
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP, Selinger CI, Mahar A, Cooper WA.
    Arch Pathol Lab Med; 2018 Aug 01; 142(8):922-928. PubMed ID: 29902067
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.
    Nambirajan A, Rana D, Samant K, Prabakaran A, Malik P, Jain D.
    J Am Soc Cytopathol; 2022 Aug 01; 11(3):154-164. PubMed ID: 35148960
    [Abstract] [Full Text] [Related]

  • 13. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
    Cha YJ, Lee JS, Kim HR, Lim SM, Cho BC, Lee CY, Shim HS.
    PLoS One; 2014 Aug 01; 9(7):e103333. PubMed ID: 25058391
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E, Choi YL, Ahn MJ, Han J.
    Pathol Res Pract; 2019 Jul 01; 215(7):152441. PubMed ID: 31085007
    [Abstract] [Full Text] [Related]

  • 20. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.
    Clin Lung Cancer; 2019 Jul 01; 20(4):e421-e429. PubMed ID: 30898567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.